|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
2
|
Miller KD, Ortiz AP, Pinheiro PS, Bandi P,
Minihan A, Fuchs HE, Tyson DM, Tortolero-Luna G, Fedewa SA, Jemal
AM and Siegel RL: Cancer statistics for the US Hispanic/Latino
population, 2021. CA Cancer J Clin. 71:466–487. 2021.PubMed/NCBI
|
|
3
|
Yang J, Xu R, Wang C, Qiu J, Ren B and You
L: Early screening and diagnosis strategies of pancreatic cancer: A
comprehensive review. Cancer Commun (Lond). 41:1257–1274. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun W, Shi Q, Zhang H, Yang K, Ke Y, Wang
Y and Qiao L: Advances in the techniques and methodologies of
cancer gene therapy. Discov Med. 27:45–55. 2019.PubMed/NCBI
|
|
5
|
Abbott M and Ustoyev Y: Cancer and the
immune system: The history and background of immunotherapy. Semin
Oncol Nurs. 35:1509232019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang Z, Wu L, Wang A, Tang W, Zhao Y, Zhao
H and Teschendorff AE: dbDEMC 2.0: Updated database of
differentially expressed miRNAs in human cancers. Nucleic Acids
Res. 45:D812–D818. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park J, Cho J and Song EJ:
Ubiquitin-proteasome system (UPS) as a target for anticancer
treatment. Arch Pharm Res. 43:1144–1161. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Johnson DE: The ubiquitin-proteasome
system: Opportunities for therapeutic intervention in solid tumors.
Endocr Relat Cancer. 22:T1–T17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang W, Huang H, Xiao Y, Wang L, Zhang T,
Fang X and Xia X: UBE2T is upregulated, predicts poor prognosis,
and promotes cell proliferation and invasion by promoting
epithelial-mesenchymal transition via inhibiting autophagy in an
AKT/mTOR dependent manner in ovarian cancer. Cell Cycle.
21:780–791. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hu W, Xiao L, Cao C, Hua S and Wu D: UBE2T
promotes nasopharyngeal carcinoma cell proliferation, invasion, and
metastasis by activating the AKT/GSK3β/β-catenin pathway.
Oncotarget. 7:15161–15172. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cui P, Li H, Wang C, Liu Y, Zhang M, Yin
Y, Sun Z, Wang Y and Chen X: UBE2T regulates epithelial-mesenchymal
transition through the PI3K-AKT pathway and plays a carcinogenic
role in ovarian cancer. J Ovarian Res. 15:1032022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ueki T, Park JH, Nishidate T, Kijima K,
Hirata K, Nakamura Y and Katagiri T: Ubiquitination and
downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T
overexpression in human breast cancer cells. Cancer Res.
69:8752–8760. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Alpi AF, Chaugule V and Walden H:
Mechanism and disease association of E2-conjugating enzymes:
Lessons from UBE2T and UBE2L3. Biochem J. 473:3401–3419. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Alagpulinsa DA, Kumar S, Talluri S,
Nanjappa P, Buon L, Chakraborty C, Samur MK, Szalat R, Shammas MA
and Munshi NC: Amplification and overexpression of E2 ubiquitin
conjugase UBE2T promotes homologous recombination in multiple
myeloma. Blood Adv. 3:3968–3972. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dutta R, Guruvaiah P, Reddi KK, Bugide S,
Bandi DS, Edwards YJK, Singh K and Gupta R: UBE2T promotes breast
cancer tumor growth by suppressing DNA replication stress. NAR
Cancer. 4:zcac0352022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hao P, Kang B, Li Y, Hao W and Ma F: UBE2T
promotes proliferation and regulates PI3K/Akt signaling in renal
cell carcinoma. Mol Med Rep. 20:1212–1220. 2019.PubMed/NCBI
|
|
17
|
Liu Y, Ji W, Yue N and Zhou W:
Ubiquitin-conjugating enzyme E2T promotes tumor stem cell
characteristics and migration of cervical cancer cells by
regulating the GRP78/FAK pathway. Open Life Sci. 16:1082–1090.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Z, Chen N, Liu C, Cao G, Ji Y, Yang W
and Jiang Q: UBE2T is a prognostic biomarker and correlated with
Th2 cell infiltrates in retinoblastoma. Biochem Biophys Res Commun.
614:138–144. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hutter C and Zenklusen JC: The cancer
genome atlas: Creating lasting value beyond its data. Cell.
173:283–285. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q,
Li B and Liu XS: TIMER2.0 for analysis of tumor-infiltrating immune
cells. Nucleic Acids Res. 48:W509–W514. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ghandi M, Huang FW, Jané-Valbuena J,
Kryukov GV, Lo CC, McDonald ER III, Barretina J, Gelfand ET,
Bielski CM, Li H, et al: Next-generation characterization of the
cancer cell line encyclopedia. Nature. 569:503–508. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu CJ, Hu FF, Xia MX, Han L, Zhang Q and
Guo AY: GSCALite: A web server for gene set cancer analysis.
Bioinformatics. 34:3771–3772. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao Y, Zhang M, Pu H, Guo S, Zhang S and
Wang Y: Prognostic implications of pan-cancer CMTM6 expression and
its relationship with the immune microenvironment. Front Oncol.
10:5859612021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yoshihara K, Shahmoradgoli M, Martínez E,
Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW,
Levine DA, et al: Inferring tumour purity and stromal and immune
cell admixture from expression data. Nat Commun. 4:26122013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yuan H, Yan M, Zhang G, Liu W, Deng C,
Liao G, Xu L, Luo T, Yan H, Long Z, et al: CancerSEA: A cancer
single-cell state atlas. Nucleic Acids Res. 47:D900–D908. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schumacher TN and Schreiber RD:
Neoantigens in cancer immunotherapy. Science. 348:69–74. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yarchoan M, Hopkins A and Jaffee EM: Tumor
mutational burden and response rate to PD-1 inhibition. N Engl J
Med. 377:2500–2501. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tada K, Kitano S, Shoji H, Nishimura T,
Shimada Y, Nagashima K, Aoki K, Hiraoka N, Honma Y, Iwasa S, et al:
Pretreatment immune status correlates with progression-free
survival in chemotherapy-treated metastatic colorectal cancer
patients. Cancer Immunol Res. 4:592–599. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Angelova M, Charoentong P, Hackl H,
Fischer ML, Snajder R, Krogsdam AM, Waldner MJ, Bindea G, Mlecnik
B, Galon J and Trajanoski Z: Characterization of the
immunophenotypes and antigenomes of colorectal cancers reveals
distinct tumor escape mechanisms and novel targets for
immunotherapy. Genome Biol. 16:642015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sanz-Pamplona R, Melas M, Maoz A, Schmit
SL, Rennert H, Lejbkowicz F, Greenson JK, Sanjuan X, Lopez-Zambrano
M, Alonso MH, et al: Lymphocytic infiltration in stage II
microsatellite stable colorectal tumors: A retrospective prognosis
biomarker analysis. PLoS Med. 17:e10032922020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu M, Li X, Huang W, Chen Y, Wang B and
Liu X: Ubiquitin-conjugating enzyme E2T(UBE2T) promotes colorectal
cancer progression by facilitating ubiquitination and degradation
of p53. Clin Res Hepatol Gastroenterol. 45:1014932021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao L, Jiang L, Wang L, He J, Yu H, Sun
G, Chen J, Xiu Q and Li B: UbcH10 expression provides a useful tool
for the prognosis and treatment of non-small cell lung cancer. J
Cancer Res Clin Oncol. 138:1951–1961. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
37
|
Zhu X, Li T, Niu X, Chen L and Ge C:
Identification of UBE2T as an independent prognostic biomarker for
gallbladder cancer. Oncol Lett. 20:442020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yu H, Xiang P, Pan Q, Huang Y, Xie N and
Zhu W: Ubiquitin-Conjugating enzyme E2T is an independent
prognostic factor and promotes gastric cancer progression. Tumour
Biol. 37:11723–11732. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Luo M and Zhou Y: Comprehensive analysis
of differentially expressed genes reveals the promotive effects of
UBE2T on colorectal cancer cell proliferation. Oncol Lett.
22:7142021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zheng YW, Gao PF, Ma MZ, Chen Y and Li CY:
Role of ubiquitin-conjugating enzyme E2T in the carcinogenesis and
progression of pancreatic cancer. Oncol Lett. 20:1462–1468. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang X, Liu Y, Leng X, Cao K, Sun W, Zhu J
and Ma J: UBE2T contributes to the prognosis of esophageal squamous
cell carcinoma. Pathol Oncol Res. 27:6325312021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Perez-Peña J, Corrales-Sánchez V, Amir E,
Pandiella A and Ocana A: Ubiquitin-conjugating enzyme E2T (UBE2T)
and denticleless protein homolog (DTL) are linked to poor outcome
in breast and lung cancers. Sci Rep. 7:175302017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang Y, Leng H, Chen H, Wang L, Jiang N,
Huo X and Yu B: Knockdown of UBE2T inhibits osteosarcoma cell
proliferation, migration, and invasion by suppressing the PI3K/Akt
signaling pathway. Oncol Res. 24:361–369. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gong YQ, Peng D, Ning XH, Yang XY, Li XS,
Zhou LQ and Guo YL: UBE2T silencing suppresses proliferation and
induces cell cycle arrest and apoptosis in bladder cancer cells.
Oncol Lett. 12:4485–4492. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang Y and Zhang Z: The history and
advances in cancer immunotherapy: Understanding the characteristics
of tumor-infiltrating immune cells and their therapeutic
implications. Cell Mol Immunol. 17:807–821. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong
F, Guo C, Wu X, Li Y, Li X, et al: Neoantigen vaccine: An emerging
tumor immunotherapy. Mol Cancer. 18:1282019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu Y, Zugazagoitia J, Ahmed FS, Henick
BS, Gettinger SN, Herbst RS, Schalper KA and Rimm DL: Immune cell
PD-L1 colocalizes with macrophages and is associated with outcome
in PD-1 pathway blockade therapy. Clin Cancer Res. 26:970–977.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ciardiello D, Vitiello PP, Cardone C,
Martini G, Troiani T, Martinelli E and Ciardiello F: Immunotherapy
of colorectal cancer: Challenges for therapeutic efficacy. Cancer
Treat Rev. 76:22–32. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Topalian SL, Drake CG and Pardoll DM:
Immune checkpoint blockade: A common denominator approach to cancer
therapy. Cancer Cell. 27:450–461. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Baretti M and Le DT: DNA mismatch repair
in cancer. Pharmacol Ther. 189:45–62. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sha D, Jin Z, Budczies J, Kluck K,
Stenzinger A and Sinicrope FA: Tumor mutational burden as a
predictive biomarker in solid tumors. Cancer Discov. 10:1808–1825.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ballhausen A, Przybilla MJ, Jendrusch M,
Haupt S, Pfaffendorf E, Seidler F, Witt J, Sanchez AH, Urban K,
Draxlbauer M, et al: The shared frameshift mutation landscape of
microsatellite-unstable cancers suggests immunoediting during tumor
evolution. Nat Commun. 11:47402020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Li J, Wu C, Hu H, Qin G, Wu X, Bai F,
Zhang J, Cai Y, Huang Y, Wang C, et al: Remodeling of the immune
and stromal cell compartment by PD-1 blockade in mismatch
repair-deficient colorectal cancer. Cancer Cell. 41:1152–1169.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Xie N, Shen G, Gao W, Huang Z, Huang C and
Fu L: Neoantigens: Promising targets for cancer therapy. Signal
Transduct Target Ther. 8:92023. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Shin SJ, Kim SY, Choi YY, Son T, Cheong
JH, Hyung WJ, Noh SH, Park CG and Kim HI: Mismatch repair status of
gastric cancer and its association with the local and systemic
immune response. Oncologist. 24:e835–e844. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Hou W, Yi C and Zhu H: Predictive
biomarkers of colon cancer immunotherapy: Present and future. Front
Immunol. 13:10323142022. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Gulubova MV, Ananiev JR, Vlaykova TI,
Yovchev Y, Tsoneva V and Manolova IM: Role of dendritic cells in
progression and clinical outcome of colon cancer. Int J Colorectal
Dis. 27:159–169. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Veglia F, Perego M and Gabrilovich D:
Myeloid-derived suppressor cells coming of age. Nat Immunol.
19:108–119. 2018. View Article : Google Scholar : PubMed/NCBI
|
